Mike Hennessy Jr.

Industry investments indicate increasing trust in the newest modalities, including mRNA approaches.

It has been a long wait, but for Alzheimer’s at least, this is the beginning of renewed hope.

Pharma's ability to continually reinvent itself will be critical in growing future business operations.

A proposed database includes key information about critical drugs, such as the country of origin and quantity, so supply chain weaknesses can be identified.

The debate surrounding drug pricing changes rages on.

COVID-19 has raised the specter of pandemic planning and the question of what can be done now to prevent future disaster.

The engine that drives pharmaceuticals forward, its workforce, is now very low on fuel.

Direct-to-consumer drug advertising has developed as a cottage industry which has been used to increase prescriptions immensely.

That wave beginning to crash over PhRMA’s gunwales may well emanate from a startup mindset, rather than Big Pharma or government policy pundits.

The restraint to not target solely the major disease groups has provided good proportion and balance for our industry.